Back
Ovid Therapeutics Quote, Financials, Valuation and Earnings
Sponsored
OVID
Sponsored
Hint at where the next big move in the market will be this month
Spot the next big move with this free book from a hedge fund manager
Sell
16
OVID
Ovid Therapeutics
Last Price:
1.16
Seasonality Move:
-0.74%
7 Day Trial
ALL ACCESS PASS
$
7
Free 23-page book shares my #1 indicator to use
Here's the 23-page free book.Ovid Therapeutics Price Quote
$1.16
-0.01 (-0.85%)
(Updated: September 20, 2024 at 11:45 AM ET)
Ovid Therapeutics Key Stats
Sell
16
Ovid Therapeutics (OVID)
is a Sell
Day range:
$1.06 - $1.17
52-week range:
$0.68 - $4.10
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
145.97
P/B ratio:
0.93%
Volume:
92.3K
Avg. volume:
211.8K
1-year change:
-69.61%
Market cap:
$83M
Revenue:
$391.7K
EPS:
$-0.43
How Much Does Ovid Therapeutics Make?
-
How Much Are Ovid Therapeutics's Sales Annually?
OVID Revenues are $391.7K -
How Much Profit Does Ovid Therapeutics's Make A Year?
OVID net income is -$52.3M
Is Ovid Therapeutics Growing As A Company?
-
What Is Ovid Therapeutics's Growth Rate Quarterly?
Quarterly YoY revenue growth is 1.25% -
What Is Ovid Therapeutics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Ovid Therapeutics Stock Price Performance
-
Did Ovid Therapeutics Stock Go Up Last Month?
Ovid Therapeutics share price went up by 2.63% last month -
Did OVID's Share Price Rise Over The Last Year?
OVID share price fell by -69.61% over the past 1 year
What Is Ovid Therapeutics 52-Week High & Low?
-
What Is Ovid Therapeutics’s 52-Week High Share Price?
Ovid Therapeutics has traded as high as $4.10 over the past 52 weeks -
What Is Ovid Therapeutics’s 52-Week Low Share Price?
Ovid Therapeutics has traded as low as $0.68 over the past 52 weeks
Ovid Therapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Ovid Therapeutics?
-
How Much Debt Does Ovid Therapeutics Have?
Total long term debt quarterly is $0 -
How Much Cash Does Ovid Therapeutics Have?
Cash and short term investments quarterly total is $77M -
What Is Ovid Therapeutics’s Book Value Per Share?
Book value per share is 1.25
Is Ovid Therapeutics Cash Flow Positive?
-
What Is OVID Cash Flow From Operations?
Cash flow from operations (TTM) is -$52.9M -
What Is Ovid Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $30.8M -
What Is Ovid Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$19.9M
Ovid Therapeutics Return On Invested Capital
-
Is Management Doing A Good Job?
OVID return on invested capital is -31.85% -
What Is Ovid Therapeutics Return On Assets?
ROA measures how assets are converting to revenues and is -22.71% -
What Is OVID Return On Equity?
ROE is a measure of profitability and is -31.85%
Ovid Therapeutics Earnings Date & Stock Price
-
What Is Ovid Therapeutics's Stock Price Today?
A single share of OVID can be purchased today for 1.17 -
What Is Ovid Therapeutics’s Stock Symbol?
Ovid Therapeutics trades on the nasdaq under the ticker symbol: OVID -
When Is Ovid Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Ovid Therapeutics is scheduled on November 1, 2024 -
When Is OVID's next ex-dividend date?
Ovid Therapeutics's next ex-dividend date is September 20, 2024 -
How To Buy Ovid Therapeutics Stock?
You can buy Ovid Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Ovid Therapeutics Competitors
-
Who Are Ovid Therapeutics's Competitors?
Below is a list of companies who compete with Ovid Therapeutics or are related in some way:
Ovid Therapeutics Dividend Yield
-
What Is OVID Dividend Yield?
Ovid Therapeutics’s dividend yield currently is 0% -
What Is Ovid Therapeutics’s Payout Ratio?
Ovid Therapeutics’s payout ratio is 0% -
When Did Ovid Therapeutics Last Pay A Dividend?
The latest dividend pay date is September 20, 2024 -
What Is Ovid Therapeutics’s Dividend Per Share?
Ovid Therapeutics pays a dividend of $0.00 per share
Ovid Therapeutics Analyst Estimates
YoY Growth | Past Surprise | |
---|---|---|
EPS: | 0% | 150.12% |
Revenue: | 125.33% | 219.59% |
Analyst Recommendations
Buy Recommendations: | 6 |
---|---|
Hold Recommendations: | 2 |
Sell Recommendations: | 0 |
Price Target: | 3.26 |
Upside from Last Price: | 178.63% |